Compounding: Hamburg, Dems Look To Shift Spotlight Away From FDA As Hearing Looms
This article was originally published in The Pink Sheet Daily
Executive Summary
After a House subcommittee announces hearing focused on whether FDA could have prevented the meningitis outbreak at the New England Compounding Center, FDA commissioner and subcommittee Democrats write about apparent outside efforts to sidestep and delay compounder inspections.
You may also be interested in...
Compounding Oversight: Could Third-Party Inspection Solve The Problem?
Iowa has contracted with a national pharmacy group to inspect facilities outside its borders. Although the program could serve as a potential model for a nationwide plan, it also could bring several problems.
FDA Compounder Inspections May Help Set New Enforcement Standard
Agency releases 483 forms from a post-crises inspection push; the effort may help FDA illustrate its inspection capabilities to Congress and states and indicate the agency’s oversight plans under the new authority it has proposed.
Parallel Scientific Advice: Is The EMA User Fee Impacting Interest?
EMA charges participants to receive scientific advice through the fledgling program, unlike the US FDA, which may not fit the budgets of some complex generic sponsors. At the same time, sponsors also may simply not be aware the program exists yet.